These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 22763881)

  • 1. Overexpression of vasoactive intestinal peptide receptors and cyclooxygenase-2 in human prostate cancer. Analysis of potential prognostic relevance.
    Fernández-Martínez AB; Carmena MJ; Arenas MI; Bajo AM; Prieto JC; Sánchez-Chapado M
    Histol Histopathol; 2012 Aug; 27(8):1093-101. PubMed ID: 22763881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression of vasoactive intestinal peptide receptors in human lung cancer.
    Szilasi M; Buglyo A; Treszl A; Kiss L; Schally AV; Halmos G
    Int J Oncol; 2011 Oct; 39(4):1019-24. PubMed ID: 21769421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations in the relative abundance of the vasoactive intestinal peptide receptors (VPAC1 and VPAC2) and functions in uterine contractility during inflammation.
    Palus K; Całka J; Jana B
    Anim Reprod Sci; 2021 Feb; 225():106680. PubMed ID: 33388613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pituitary adenylate cyclase-activating peptide/vasoactive intestinal peptide receptors in human normal mammary gland and breast cancer tissue.
    García-Fernández MO; Collado B; Bodega G; Cortés J; Ruíz-Villaespesa A; Carmena MJ; Prieto JC
    Gynecol Endocrinol; 2005 Jun; 20(6):327-33. PubMed ID: 16019382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer: antagonistic action of a growth-hormone-releasing hormone analog.
    Collado B; Carmena MJ; Sánchez-Chapado M; Ruíz-Villaespesa A; Bajo AM; Fernández-Martínez AB; Varga JL; Schally AV; Prieto JC
    Int J Oncol; 2005 Jun; 26(6):1629-35. PubMed ID: 15870879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
    Barberi M; Muciaccia B; Morelli MB; Stefanini M; Cecconi S; Canipari R
    Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of VPAC1 and VPAC2 in VIP mediated inhibition of rat pulmonary artery and aortic smooth muscle cell proliferation.
    St Hilaire RC; Murthy SN; Kadowitz PJ; Jeter JR
    Peptides; 2010 Aug; 31(8):1517-22. PubMed ID: 20452385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VPAC1 (vasoactive intestinal peptide (VIP) receptor type 1) G protein-coupled receptor mediation of VIP enhancement of murine experimental colitis.
    Yadav M; Huang MC; Goetzl EJ
    Cell Immunol; 2011; 267(2):124-32. PubMed ID: 21295288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VIP attenuation of the severity of experimental pancreatitis is due to VPAC1 receptor-mediated inhibition of cytokine production.
    Kojima M; Ito T; Oono T; Hisano T; Igarashi H; Arita Y; Kawabe K; Coy DH; Jensen RT; Nawata H
    Pancreas; 2005 Jan; 30(1):62-70. PubMed ID: 15632701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide stimulate interleukin-6 production in prostate cancer cells and prostatic epithelial cells.
    Nagakawa O; Junicho A; Akashi T; Koizumi K; Matsuda T; Fuse H; Saiki I
    Oncol Rep; 2005 Jun; 13(6):1217-21. PubMed ID: 15870945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Relevance of VPAC1 Receptor Expression in Early Arthritis: Association with IL-6 and Disease Activity.
    Seoane IV; Ortiz AM; Piris L; Lamana A; Juarranz Y; García-Vicuña R; González-Álvaro I; Gomariz RP; Martínez C
    PLoS One; 2016; 11(2):e0149141. PubMed ID: 26881970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vasoactive intestinal peptide and its receptors in human ovarian cortical follicles.
    Gabbay-Benziv R; Ao A; Fisch B; Zhang L; Oron G; Kessler-Icekson G; Ben-Haroush A; Krissi H; Abir R
    PLoS One; 2012; 7(5):e37015. PubMed ID: 22623971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radical reversal of vasoactive intestinal peptide (VIP) receptors during early lymphopoiesis.
    Vomhof-DeKrey EE; Sandy AR; Failing JJ; Hermann RJ; Hoselton SA; Schuh JM; Weldon AJ; Payne KJ; Dorsam GP
    Peptides; 2011 Oct; 32(10):2058-66. PubMed ID: 21878358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic relevance of cyclooxygenase-2 (COX-2) expression in Chinese patients with prostate cancer.
    Bin W; He W; Feng Z; Xiangdong L; Yong C; Lele K; Hongbin Z; Honglin G
    Acta Histochem; 2011 Feb; 113(2):131-6. PubMed ID: 19836060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A lymphocyte-generated fragment of vasoactive intestinal peptide with VPAC1 agonist activity and VPAC2 antagonist effects.
    Summers MA; O'Dorisio MS; Cox MO; Lara-Marquez M; Goetzl EJ
    J Pharmacol Exp Ther; 2003 Aug; 306(2):638-45. PubMed ID: 12750439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts.
    Juarranz Y; Gutiérrez-Cañas I; Santiago B; Carrión M; Pablos JL; Gomariz RP
    Arthritis Rheum; 2008 Apr; 58(4):1086-95. PubMed ID: 18383383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulation of vasoactive intestinal peptide and altered expression of its receptors in rat diabetic cardiomyopathy.
    Dvoráková MC; Pfeil U; Kuncová J; Svíglerová J; Galvis G; Krasteva G; König P; Grau V; Slavíková J; Kummer W
    Cell Tissue Res; 2006 Mar; 323(3):383-93. PubMed ID: 16344947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered expression of vasoactive intestinal peptide receptors in T lymphocytes and aberrant Th1 immunity in multiple sclerosis.
    Sun W; Hong J; Zang YC; Liu X; Zhang JZ
    Int Immunol; 2006 Dec; 18(12):1691-700. PubMed ID: 17077178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
    Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
    Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atypical nuclear localization of VIP receptors in glioma cell lines and patients.
    Barbarin A; Séité P; Godet J; Bensalma S; Muller JM; Chadéneau C
    Biochem Biophys Res Commun; 2014 Nov; 454(4):524-30. PubMed ID: 25450687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.